I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

5000

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms
Breast Cancer
Breast Tumors
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
HER2-positive Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Hormone Receptor Negative Tumor
Early-stage Breast Cancer
Locally Advanced Breast Cancer

Interventions

DRUG: Standard Therapy
DRUG: AMG 386 with or without Trastuzumab
DRUG: AMG 479 (Ganitumab) plus Metformin
DRUG: MK-2206 with or without Trastuzumab
DRUG: AMG 386 and Trastuzumab
DRUG: T-DM1 and Pertuzumab
DRUG: Pertuzumab and Trastuzumab
DRUG: Ganetespib
DRUG: ABT-888
DRUG: Neratinib
DRUG: PLX3397
DRUG: Pembrolizumab - 4 cycle
DRUG: Talazoparib plus Irinotecan
DRUG: Patritumab and Trastuzumab
DRUG: Pembrolizumab - 8 cycle
DRUG: SGN-LIV1A
DRUG: Durvalumab plus Olaparib
DRUG: SD-101 + Pembrolizumab
DRUG: Tucatinib plus trastuzumab and pertuzumab
DRUG: Cemiplimab

Sponsor

QuantumLeap Healthcare Collaborative